- AngioDynamics (ANGO, Financial) delivered a 12.7% year-over-year increase in net sales in Q4 2025, reaching $80.2 million.
- The company's Med Tech segment experienced significant growth, with a 22% rise compared to the prior year.
- Adjusted EBITDA for the full fiscal year 2025 was $7.6 million, demonstrating profitability despite tariff-related headwinds.
AngioDynamics, Inc. (ANGO), a leader in transformative medical technology, reported their financial results for the fourth quarter and full fiscal year ending May 31, 2025, highlighting robust performance and strategic advancements. The company showed a 12.7% increase in net sales for Q4 2025, amounting to $80.2 million, with its Med Tech division contributing $35.8 million, up 22% from the previous year.
The company's gross margin for the quarter stood at 52.7%, affected by a $1.6 million tariff impact. On a pro forma basis, excluding certain divestitures, AngioDynamics reported an adjusted EBITDA of $3.4 million for the fourth quarter, marking a significant improvement from the $1.5 million reported in Q4 2024. The U.S. market contributed $67.5 million, whereas international sales grew by 22.8% to $12.7 million compared to the prior year.
For the full fiscal year 2025, AngioDynamics achieved net sales of $292.7 million, an 8.1% increase from the previous year. The Med Tech segment led the growth with a 19.5% rise in sales, while the Med Device segment saw a slight increase. The company's adjusted loss per share improved from $(0.45) in 2024 to $(0.25) in 2025. By the end of the fiscal year, AngioDynamics maintained a cash balance of $55.9 million, surpassing expectations.
Looking forward to fiscal 2026, AngioDynamics projects net sales between $305 million and $310 million, with expectations of positive free cash flow throughout the year, despite anticipated tariff impacts estimated between $4 million and $6 million.
